Stem Cells
Trial studying adult mesenchymal stem cells on heart attack victims announced
Published in Blood Weekly, April 28th, 2005
"We are extremely enthusiastic about this study, which represents the first use of an allogeneic adult stem cell to treat the consequences of heart attack in humans. The trial design is supported by an extensive series of preclinical studies performed in animal models that demonstrate that MSCs safely and effectively reduce the damage caused by heart attack," said lead investigator Dr. Joshua Hare, director of Heart Failure and Cardiac Transplantation and the Cardiobiology Section of the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-04-28)
More Articles from Blood Weekly
- Sickle Cell Disease
Management of sickle cell disease reviewed - Stem Cell Transplantation
Time to positivity difference predicts catheter-related bacteremia after HSCT - Stem Cell Transplantation
Younger age/days of apheresis/male gender predict increased yield of CD34+ cells - Tissue Engineering
Bone scaffold demineralization influences osteogenic differentiation of BMSCs - Tissue Engineering
Collagen nerve graft structural parameters influence nerve regeneration - Acute Promyelocytic Leukemia
Sumoylation site in PML/RARA deemed essential for leukemic transformation - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
